Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.

For more information about GOA, visit www.globaloncologyacademy.org.

Episodes 1-16 of 271

Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
- Hallie Blevins, PhD.
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Ryan Quigley
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Global Oncology Academy
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Global Oncology Academy
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Project Oncology®
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
- Charles Turck, PharmD, BCPS, BCCCP
- Virginia Kaklamani, MD
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
- Marlene Mimi Maeusli, PhD.
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Project Oncology®
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
- Jennifer Caudle, DO
- Hope S. Rugo, MD, FASCO
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Project Oncology®
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
- Paola Marignani, PhD, EMBA
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
- John Cho, MD, PhD, FRCPC
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
- John Cho, MD, PhD, FRCPC
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Project Oncology®
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
- Paola Marignani, PhD, EMBA
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Project Oncology®
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
- Ryan Quigley
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
Advances in Women's Health
Clinical Outcomes of Radiation vs. Chemoradiation in Recurrent Endometrial Cancer
- Ann Klopp, M.D., Ph.D.